Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Morgensztern

Showing results (21-30 of 184) with videos related to

Pageof 19
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Nivolumab and Pembrolizumab for Non-Small Cell Lung CancerDaniel Morgensztern, Roy S Herbst
Pharmacology & Therapeutics|June 6, 2017
Treatment advances in small cell lung cancer (SCLC)Saiama N Waqar, Daniel Morgensztern
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Prognostic biomarkers in diffuse large B-cell lymphomaIzidore S Lossos, Daniel Morgensztern
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2009
Novel cytotoxic agentsDaniel Morgensztern, Chandra P Belani
The Lancet. Oncology|November 11, 2018
Lorlatinib: a new-generation drug for ALK-positive NSCLCSaiama N Waqar, Daniel Morgensztern
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): impressions from MONET (the motesanib NSCLC efficacy and tolerability study)Daniel Morgensztern, Roy S Herbst
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Vaccines and immunotherapy for non-small cell lung cancerDaniel Morgensztern, Boone Goodgame, Ramaswamy Govindan
Cancer Cell|August 29, 2020
Mastering the Complex Targeted Therapy for Non-small Cell Lung CancerSiddhartha Devarakonda, Ramaswamy Govindan, Daniel Morgensztern
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Genomic landscape of squamous cell carcinoma of the lungDaniel Morgensztern, Siddhartha Devarakonda, Ramaswamy Govindan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2008
EGFR inhibitors as first-line therapy in advanced non-small cell lung cancerThomas Fong, Daniel Morgensztern, Ramaswamy Govindan
Pageof 19

Showing results (21-30 of 184) with videos related to

Sort By:
Pageof 19
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2016
Nivolumab and Pembrolizumab for Non-Small Cell Lung CancerDaniel Morgensztern, Roy S Herbst
Pharmacology & Therapeutics|June 6, 2017
Treatment advances in small cell lung cancer (SCLC)Saiama N Waqar, Daniel Morgensztern
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2006
Prognostic biomarkers in diffuse large B-cell lymphomaIzidore S Lossos, Daniel Morgensztern
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 29, 2009
Novel cytotoxic agentsDaniel Morgensztern, Chandra P Belani
The Lancet. Oncology|November 11, 2018
Lorlatinib: a new-generation drug for ALK-positive NSCLCSaiama N Waqar, Daniel Morgensztern
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 4, 2012
Multitargeted tyrosine kinase inhibitors in unselected patients with advanced non-small-cell lung cancer (NSCLC): impressions from MONET (the motesanib NSCLC efficacy and tolerability study)Daniel Morgensztern, Roy S Herbst
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 25, 2010
Vaccines and immunotherapy for non-small cell lung cancerDaniel Morgensztern, Boone Goodgame, Ramaswamy Govindan
Cancer Cell|August 29, 2020
Mastering the Complex Targeted Therapy for Non-small Cell Lung CancerSiddhartha Devarakonda, Ramaswamy Govindan, Daniel Morgensztern
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 30, 2013
Genomic landscape of squamous cell carcinoma of the lungDaniel Morgensztern, Siddhartha Devarakonda, Ramaswamy Govindan
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2008
EGFR inhibitors as first-line therapy in advanced non-small cell lung cancerThomas Fong, Daniel Morgensztern, Ramaswamy Govindan
Pageof 19